Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. April 2018 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR to Present at Two Upcoming Conferences

LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
12. Februar 2018 07:00 ET | Quelle: ProQR Therapeutics N.V.; Foundation Fighting Blindness

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting...
06. Februar 2018 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR to Present at Upcoming Scientific Meeting and Investor Conference

LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
24. Oktober 2017 07:00 ET | Quelle: ProQR Therapeutics N.V.

ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

LEIDEN, the Netherlands, Oct. 24, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...